

**MISSISSIPPI DIVISION OF MEDICAID**  
**Pharmacy & Therapeutics Committee**  
**Woolfolk Building**  
**Conference Center East, Room 145**  
**Jackson, MS 39201-1399**  
**February 12, 2019**  
**10:00am to 5:00pm**

**AGENDA**

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of October 23, 2018 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Drug Class Announcements
- VII. Public Comment
- VIII. Therapeutic Class Reviews-
  - a. Antiviral, Influenza Agents
  - b. Platelet Stimulating Agents
- IX. New Drug/New Generic Reviews
  - a. Acne Agents, Retinoids –
    - 1. Altreno (tretinoin) - financial review only
    - 2. Plixda (adapalene) - financial review only
  - b. Analgesics, Narcotic - Short Acting – Roxybond (oxycodone)
  - c. Analgesics/Anesthetics (Topical) – Ztlido (lidocaine)
  - d. Androgenic Agents – Xyosted (testosterone enanthate)
  - e. Antibiotics (GI) – Firvanq (vancomycin hydrochloride)
  - f. Anticonvulsants, Adjuvants – Epidiolex (cannabidiol)
  - g. Anticonvulsants, Selected Benzodiazepines – Sympazan (clobazam)
  - h. Antimigraine Agents, Calcitonin Gene Related Peptide Inhibitor –
    - 1. Ajoovy (fremanezumab-vfrm)
    - 2. Emgality (galcanezumab-gnlm)
  - i. Antineoplastics - Selected Systemic Enzyme Inhibitors –
    - 1. Braftovi (encorafenib)
    - 2. Lorbrena (lorlatinib)
    - 3. Mektovi (binimetinib)
    - 4. Talzenna (talazoparib)
    - 5. Tibsovo (ivosidenib)
    - 6. Vizimpro (dacomitinib)
  - j. Antipsychotics, Injectable, Atypicals – Perseris (risperidone)
  - k. Antiretrovirals –Combination Products, Single Tablet Therapies
    - 1. Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
    - 2. Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate)

- l. Antiretrovirals-Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) – Pifeltro (doravirine)
  - m. Beta Blockers, Antianginals & Sinus Node Agents – Kapsargo Sprinkles (metoprolol succinate) - financial review only
  - n. Colony Stimulating Factors – Nivestym (filgrastim-aafi) - financial review only
  - o. Cytokine & CAM Antagonists –
    - 1. Ilumya (tildrakizumab-asmn)
    - 2. Olumiant (baricitinib)
  - p. Hereditary Angioedema – Takhzyro (lanadelumab-flyo)
  - q. Lipotropics, Statins – Zypitamag (pitavastatin) - financial review only
  - r. Miscellaneous – Siklos (hydroxyurea)
  - s. Ophthalmic Antibiotics, Antibiotic Steroid Combinations – Inveltys (loteprednol etabonate)
  - t. Ophthalmic, Glaucoma Agents, Prostaglandin Analogs – Xelpros (latanoprost) - financial review only
  - u. Opiate Dependence Treatments – Lucemyra (lofexidine)
- X. Division of Medicaid Update
- XI. Next Meeting Dates
- a. Tuesday, May 7,2019
  - b. Tuesday, August 13, 2019
  - c. Tuesday, October 22,2019
- XII. Adjournment